Sarepta Stock Plunges 19.79% Despite 80.2% Revenue Surge

On May 7, 2025, Sarepta's stock experienced a significant drop of 19.79% in pre-market trading, reflecting a sharp decline in investor sentiment.

Sarepta Therapeutics reported a substantial increase in revenue for the first quarter of 2025, with total revenue reaching $744.86 million, marking an 80.2% year-over-year growth. This growth was primarily driven by a 70% increase in product revenue, which amounted to $612 million. However, the company's earnings and revenue surprises for the quarter were notably negative, with earnings surprises of -1,077.14% and revenue surprises of 6.68%.

Despite the strong revenue performance, Sarepta slashed its 2025 revenue forecast, now expecting full-year product revenue to range between $2.3 billion and $2.6 billion. This revised outlook is a significant reduction from the previous estimate of $2.9 billion to $3.1 billion. The company also reported a net loss of $161.4 million for the first quarter, or $1.36 per share, compared to a net loss of $135.6 million, or $1.33 per share, in the same period last year. Research and development expenses rose to $99.8 million, contributing to the overall financial performance.